Partners Group completed the acquisition of Pharmathen from BC Partners for €1.6bn.

Partners Group, a global private markets firm, completed the acquisition of Pharmathen, a European pharmaceutical company, from BC Partners, an international investment firm, for €1.6bn ($1.9bn). "Pharmathen is very well-regarded by the broader pharmaceutical industry as an innovative and forward-thinking company. It is a mission-critical partner to its B2B clients whose advanced pharmaceutical technologies create real societal impact and optimize treatment outcomes for patients. Partners Group will lend its operational expertise to support Pharmathen as it expands to meet increasing demand for affordable Generics and positions for long-term, sustainable growth. We are delighted to back Dimitris and his talented management team and look forward to working with them," Pascal Noth, Partners Group Managing Director.